{"transactions":[{"id":705373,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock Units","published_at":"2026-07-21T20:00:30.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 250 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":250,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001493152-26-034069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226034069/ownership.xml","form_type":"4"}},{"id":2383648,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2022-02-23T01:01:11.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":20000,"reported_value":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $20,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001214/ownership.xml","form_type":"4"}},{"id":2576519,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-09-08T21:00:44.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-21-022218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022218/ownership.xml","form_type":"4"}},{"id":2632516,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-07-16T21:37:41.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":357412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant."}],"balance_after":357412,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":357412},"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2632515,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:37:41.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":3292,"ownership":{"direct":false,"nature":"By Artius Bioconsulting"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3291720},"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2632514,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-16T21:37:41.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":3291720,"ownership":{"direct":false,"nature":"By Artius Bioconsulting"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":3330647,"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2891257,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:31:51.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000321/ownership.xml","form_type":"4"}},{"id":2891256,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:31:51.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000321/ownership.xml","form_type":"4"}},{"id":2943534,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:03.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":43479,"price":3.3,"value":143480.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as a long-term incentive grant equal to 25% of reporting person's annual base salary. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":108697,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":43479},"source":{"system":"sec-edgar","filing":"0001683168-20-004323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004323/ownership.xml","form_type":"4"}},{"id":2943533,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:03.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":65218,"price":3.3,"value":215219.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as part of the reporting person's annual base salary. RSUs will vest 100% on August 31, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":65218,"derivative":{"exercise_date":"2021-08-31","underlying":"Common Stock","underlying_shares":65218},"source":{"system":"sec-edgar","filing":"0001683168-20-004323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004323/ownership.xml","form_type":"4"}},{"id":4177041,"issuer":{"id":83494,"kind":"organization","name":"Avid Bioservices, Inc.","symbol":"CDMO"},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-11-01T15:12:05.000Z","date":"2017-10-31","kind":"other","acquired":true,"shares":1398,"price":3.8675,"value":5406.765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the issuer's employee stock purchase plan on October 31, 2017."}],"balance_after":34646,"source":{"system":"sec-edgar","filing":"0001683168-17-002784","document":"king_frm4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704562/000168316817002784/king_frm4.xml","form_type":"4"}},{"id":4342728,"issuer":{"id":83494,"kind":"organization","name":"Avid Bioservices, Inc.","symbol":"CDMO"},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-04-28T18:56:05.000Z","date":"2017-04-28","kind":"other","acquired":true,"shares":19941,"price":0.2712,"value":5407.9992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the issuer's employee stock purchase plan on April 28, 2017"}],"balance_after":232730,"source":{"system":"sec-edgar","filing":"0001683168-17-001048","document":"king_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704562/000168316817001048/king_f4.xml","form_type":"4"}},{"id":4571434,"issuer":{"id":83494,"kind":"organization","name":"Avid Bioservices, Inc.","symbol":"CDMO"},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-11-01T20:02:20.000Z","date":"2016-10-31","kind":"other","acquired":true,"shares":18826,"price":0.2864,"value":5391.7664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the issuer's employee stock purchase plan on October 31, 2016."}],"balance_after":212789,"source":{"system":"sec-edgar","filing":"0001683168-16-000445","document":"king_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704562/000168316816000445/king_f4.xml","form_type":"4"}}]}